AN2 Therapeutics (ANTX)

• Market cap: $37.6M
• 1 day: 0.81%
• 5 days: -8.76%
• 1 month: -7.41%
• 3 months: -3.85%
• 6 months: 20.19%
• Year to date: -10.07%
• 1 year: -58.47%
• 5 years: -91.88%
• 10 years: -91.88%
• Sector: Healthcare
• Industry: Biotechnology

About: AN2 Therapeutics Inc is a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform. The company has a pipeline of boron-based compounds in development for Chagas disease, non-tuberculous mycobacterial (NTM) and melioidosis, along with early-stage programs focused on targets in infectious diseases and oncology.

Employees: 36

Fund manager confidence

Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)

100% more first-time investments, than exits

New positions opened: 12 | Existing positions closed: 6

71% more repeat investments, than reductions

Existing positions increased: 12 | Existing positions reduced: 7

39% more capital invested

Capital invested by funds: $14.5M [Q3] → $20M (+$5.59M) [Q4]

19% more funds holding

Funds holding: 32 [Q3] → 38 (+6) [Q4]

3.34% more ownership

Funds ownership: 45.29% [Q3] → 48.62% (+3.34%) [Q4]

0% more funds holding in top 10

Funds holding in top 10: 1 [Q3] → 1 (+0) [Q4]

Research analyst outlook

2 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $5 300% upside
• Avg. target: $5 300% upside
• High target: $5 300% upside

2 analyst ratings

• positive: 2 100%
• neutral: 0 0%
• negative: 0 0%

Citizens Capital Markets Roy Buchanan 17% 1-year accuracy 4 / 24 met price target	300% upside $5	Market Outperform Reiterated	26 Mar 2025
JMP Securities Roy Buchanan 17% 1-year accuracy 4 / 24 met price target	300% upside $5	Market Outperform Reiterated	3 Feb 2025